See the DrugPatentWatch profile for Insulin
What is Insulin Glargine Max Solo?
Insulin glargine max solo refers to a specific formulation of insulin glargine, a long-acting basal insulin. While "max solo" is not a standard pharmaceutical designation, it likely refers to a higher concentration or a proprietary formulation intended for a singular use, possibly indicating a single-dose or single-patient injection device. Insulin glargine is used to manage blood sugar levels in individuals with diabetes.
How does Insulin Glargine Work?
Insulin glargine mimics the action of naturally produced insulin. It is designed to provide a steady, prolonged release of insulin over a 24-hour period. This helps to control fasting blood glucose levels by reducing hepatic glucose production and increasing glucose uptake by peripheral tissues.
When does Insulin Glargine Patent Exclusivity End?
The patent landscape for insulin glargine is complex and involves multiple patents covering the molecule, formulations, and methods of use. For instance, patents related to the original Lantus® formulation have expired or are nearing expiration in various regions. However, secondary patents, such as those for newer formulations like Toujeo® (a higher concentration insulin glargine), have different expiration timelines. Information on specific patent expiries for insulin glargine products can be found on sites like DrugPatentWatch.com [1].
What are the Different Formulations of Insulin Glargine?
Insulin glargine is available in several concentrations and delivery devices. The most common are:
* Lantus®: A standard concentration (100 units/mL) basal insulin.
* Toujeo®: A higher concentration (300 units/mL) basal insulin, which allows for smaller injection volumes.
There can also be variations in the delivery pens used for these formulations.
Can Biosimilars of Insulin Glargine Be Marketed?
Yes, biosimilar versions of insulin glargine are available in many markets. These biosimilars are highly similar to the reference product (e.g., Lantus®) and have demonstrated no clinically meaningful differences in terms of safety, purity, and potency. The availability of biosimilars can increase competition and potentially lower costs for patients and healthcare systems.
What is the Clinical Data on Insulin Glargine?
Numerous clinical trials have established the efficacy and safety of insulin glargine in managing type 1 and type 2 diabetes. Studies have shown that it effectively reduces HbA1c levels and fasting plasma glucose. Like other insulins, potential side effects include hypoglycemia (low blood sugar), injection site reactions, and weight gain.
Who Manufactures Insulin Glargine Products?
The original insulin glargine product, Lantus®, was developed by Sanofi. Sanofi also produces the higher concentration formulation, Toujeo®. Several other pharmaceutical companies have developed and market biosimilar versions of insulin glargine.
What are the Risks Associated with Insulin Glargine?
The primary risk associated with insulin glargine, as with all insulins, is hypoglycemia. Other potential risks include:
* Allergic reactions
* Lipodystrophy (changes in fat tissue at injection sites)
* Hypokalemia (low potassium levels)
It is crucial for patients to monitor their blood glucose levels closely and to be aware of the signs and symptoms of hypoglycemia.
---
Sources
[1] DrugPatentWatch.com